Today: 2 February 2026
Subscribe
Browse Category

NASDAQ:KNSA News 13 January 2026

KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

New York, Jan 13, 2026, 16:15 EST — After-hours Kiniksa Pharmaceuticals International, plc saw its shares drop 6.1% to $38.61 on Tuesday, following the release of updated revenue forecasts for its key drug ARCALYST. The stock briefly dipped to an intraday low of $38.27. Yahoo Finance The move matters because ARCALYST is carrying the load: it serves as the company’s…
13 January 2026
·····

Stock Market Today

  • Frank Rimerman Advisors Increases Pfizer Stake by 27.6% in Q3
    February 2, 2026, 10:43 AM EST. Frank Rimerman Advisors LLC raised its Pfizer Inc. (NYSE:PFE) holdings by 27.6% in the third quarter, acquiring 42,634 additional shares to hold 196,970 in total, valued at about $5.02 million. Other institutional investors also boosted positions, including Fiduciary Alliance LLC (+46.4%), Vista Investment Partners LLC (+236.1%), and Generali Investments (+76.4%). Pfizer, a major biopharmaceutical firm, reported Q3 earnings surpassing estimates with $0.87 EPS versus $0.79 expected, though revenue of $16.65 billion missed forecasts. The stock trades near a 1-year high at $26.43, holding a market cap of $150.24 billion alongside a P/E ratio of 15.36. Institutional investors currently own 68.36% of Pfizer shares.
Go toTop